An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

Stopped early · Phase 1/Phase 2

Conditions studied: Kidney Failure

In brief

This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency

Key facts

Study ID

NCT00150319

Run by

Pfizer

People needed

1

Starts

2005-06-01

Expected to finish

2005-10-01

Last updated by the study team

2008-09-29

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with moderate renal insufficiency

You may not qualify if…

• Active infection

Where it is running

• Pfizer Investigational Site — New Orleans, Louisiana, United States
• Pfizer Investigational Site — New Orleans, Louisiana, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — Knoxville, Tennessee, United States
• Pfizer Investigational Site — Austin, Texas, United States
• Pfizer Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.